Storia in 8 fonti

Moderna Is Just The Start: Why AI-Focused Money Might Flow Into Biotech

Moderna stock catches the eye of investors looking for the next big AI play.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo2 h fa

Moderna Is Just The Start: Why AI-Focused Money Might Flow Into Biotech

Moderna stock catches the eye of investors looking for the next big AI play.

originale

benzinga.com

Timeline cronologica

mercoledì 19 agosto 2026·endpoints.news
For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars
Moderna shares surged after positive Phase 3 results for its Merck-partnered melanoma cancer vaccine, boosting confidence in its portfolio beyond Covid-19.
mercoledì 19 agosto 2026·morningstar.com
Dow Jones Top Company Headlines at 3 PM ET: Moderna Shares More Than Double on Success of mRNA Cancer Vaccine | OpenAI's ...
Moderna Shares More Than Double on Success of mRNA Cancer Vaccine

1 g fa

Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK)

Moderna and Merck posted the first Phase 3 success for individualized mRNA cancer therapy (intismeran + Keytruda), marking mRNA's pivot from COVID vaccines to personalized oncology. This unlocks a multi-billion ecosystem—genomics, AI diagnostics, sequencing—potentially extending Keytruda's $31.7B revenue and reshaping precision-medicine investment thesis.

Leggi questa versione → originale

endpoints.news1 g fa

For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars

Moderna shares surged after positive Phase 3 results for its Merck-partnered melanoma cancer vaccine, boosting confidence in its portfolio beyond Covid-19.

Leggi questa versione → originale

hindustantimes.com1 g fa

Moderna stock drops 12% after 177% surge: Here’s what Wall Street says about MRNA

Moderna-Merck Phase 3: intismeran (mRNA + Keytruda) improves recurrence-free survival in melanoma; stock surged 177%, fell 12% on profit-taking. Wall Street consensus: real value depends on cancer platform replicability across tumors and adoption, not melanoma opportunity.

Leggi questa versione → originale

forbes.com1 g fa

Why Is Moderna Stock Down Today?

Moderna's personalized cancer vaccine (mRNA + Keytruda) reduced melanoma recurrence; stock jumped 176%, dropped 25% Thursday on profit-taking. The trial validates mRNA oncology beyond vaccines, marking Moderna's pivot from COVID to profitability—inflection point for biotech-AI investment.

Leggi questa versione → originale

morningstar.com1 g fa

Dow Jones Top Company Headlines at 3 PM ET: Moderna Shares More Than Double on Success of mRNA Cancer Vaccine…

Analog Devices Q3 profit surged on AI data center demand; OpenAI pledged customer-data non-retention vs Anthropic to win enterprise deals. IT managers must now dual-evaluate foundation model vendors: capex feasibility AND data governance frameworks—vendor selection criteria now include compliance, not just capability.

Leggi questa versione → originale

mercoledì 19 agosto 2026·

axios.com

Moderna and Merck shares soar on mRNA cancer vaccine

The results come at a pivotal moment for Moderna and mRNA research.

mercoledì 19 agosto 2026·

morningstar.com

Dow Jones Top Company Headlines at 5 PM ET: Moderna Shares More Than Double on Success of mRNA Cancer Vaccine | OpenAI's ...

Moderna Shares More Than Double on Success of mRNA Cancer Vaccine

mercoledì 19 agosto 2026·

benzinga.com

Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK)

MRK, MRNA's cancer vaccine breakthrough could revive the mRNA trade, putting biotech and genomics ETFs back in focus.

giovedì 20 agosto 2026·

forbes.com

Why Is Moderna Stock Down Today?

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.

giovedì 20 agosto 2026·

morningstar.com

Dow Jones Top Company Headlines at 7 PM ET: Moderna Shares More Than Double on Success of mRNA Cancer Vaccine | OpenAI's ...

Moderna Shares More Than Double on Success of mRNA Cancer Vaccine

giovedì 20 agosto 2026·

benzinga.com

Elon Musk Backs mRNA As Moderna's Stock Soars on Cancer Vaccine Win - Moderna (NASDAQ:MRNA)

Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software problem.

giovedì 20 agosto 2026·

hindustantimes.com

Moderna stock drops 12% after 177% surge: Here’s what Wall Street says about MRNA

Moderna stock falls 12% after a 177% surge as investors weigh the intismeran cancer vaccine win, future demand, pricing and other cancer trials. | Business News

giovedì 20 agosto 2026·

benzinga.com

Moderna's Intismeran Close to Keytruda Style Oncology Opportunity: Analyst - Moderna (NASDAQ:MRNA)

William Blair upgraded Moderna to Outperform, citing higher intismeran approval odds and a multibillion-dollar oncology sales opportunity.

giovedì 20 agosto 2026·

expansion.com

Moderna desata la euforia en los mercados

Moderna se dio a conocer en el campo de las enfermedades infecciosas y, desde la pandemia, ha buscado con urgencia una nueva especialidad. Este mi�rcoles lo consigui�: su vacuna...

venerdì 21 agosto 2026·

investors.com

Moderna Is Just The Start: Why AI-Focused Money Might Flow Into Biotech

Moderna stock catches the eye of investors looking for the next big AI play.

Moderna Is Just The Start: Why AI-Focused Money Might Flow Into Biotech

Timeline cronologica

For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars

Dow Jones Top Company Headlines at 3 PM ET: Moderna Shares More Than Double on Success of mRNA Cancer Vaccine | OpenAI's ...

Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK)

For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars

Moderna stock drops 12% after 177% surge: Here’s what Wall Street says about MRNA

Why Is Moderna Stock Down Today?

Dow Jones Top Company Headlines at 3 PM ET: Moderna Shares More Than Double on Success of mRNA Cancer Vaccine…

Moderna and Merck shares soar on mRNA cancer vaccine

Dow Jones Top Company Headlines at 5 PM ET: Moderna Shares More Than Double on Success of mRNA Cancer Vaccine | OpenAI's ...

Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK)

Why Is Moderna Stock Down Today?

Dow Jones Top Company Headlines at 7 PM ET: Moderna Shares More Than Double on Success of mRNA Cancer Vaccine | OpenAI's ...

Elon Musk Backs mRNA As Moderna's Stock Soars on Cancer Vaccine Win - Moderna (NASDAQ:MRNA)

Moderna stock drops 12% after 177% surge: Here’s what Wall Street says about MRNA

Moderna's Intismeran Close to Keytruda Style Oncology Opportunity: Analyst - Moderna (NASDAQ:MRNA)

Moderna desata la euforia en los mercados

Moderna Is Just The Start: Why AI-Focused Money Might Flow Into Biotech